CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure The spectrum of heart failure: value of left ventricular ejection fraction and its moving trajectories Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure

Original Research2021 Nov;23(11):1858-1871.

JOURNAL:Eur J Heart Fail. Article Link

Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure

NR Pugliese, F Paneni, M Mazzola et al. Keywords: HF; cardiopulmonary-echocardiography exercise stressepicardial adipose tissue;

ABSTRACT

AIMS - We evaluated the impact of echocardiographic epicardial adipose tissue (EAT) on cardiovascular haemodynamics, metabolic profile and prognosis in heart failure (HF) using combined cardiopulmonary-echocardiography exercise stress.

 

METHODS AND RESULTS - We analysed EAT thickness of HF patients with reduced (HFrEF, n = 205) and preserved (HFpEF, n = 188) ejection fraction, including 44 controls. HFpEF patients displayed the highest EAT, while HFrEF patients had lower values than controls. EAT showed an inverse correlation with natriuretic peptides, troponin T and C-reactive protein in HFrEF, while having a direct association with troponin T and C-reactive protein in HFpEF. EAT was independently associated with peak oxygen consumption (VO2) and peripheral extraction (AVO2diff), regardless of body mass index. EAT was inversely correlated with peak VO2 and AVO2diff in HFpEF, while a direct association was observed in HFrEF, where lower EAT values were associated with worse left ventricular systolic dysfunction. In HFpEF, increased EAT was related to right ventriculoarterial (tricuspid annular plane systolic excursion/systolic pulmonary artery pressure) uncoupling. After 21 months of follow-up, 146 HF hospitalizations and 34 cardiovascular deaths were recorded in the HF population. Cox multivariable analysis supported an independent differential role of EAT in HF cohorts (interaction P = 0.01): higher risk of adverse events for increasing EAT in HFpEF [hazard ratio (HR) 1.12, 95% confidence interval (CI) 1.041.37] and for decreasing EAT in HFrEF (HR 0.75, 95% CI 0.540.91).

 

CONCLUSION - In HFpEF, EAT accumulation is associated with worse haemodynamic and metabolic profile, also affecting survival. Conversely, lower EAT values imply higher left ventricular dysfunction, global functional impairment and adverse prognosis in HFrEF.